Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.
WHY WE'RE FUNDRAISING WITH THE JIMMY FUND WALK TO FIGHT CANCER
Katherine Janeway, MD, MMSc, is a pediatric oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Her clinical title is Senior Physician and in recognition of her leadership in the field, Boston Magazine named Dr. Janeway a Top Doctor in 2020. She is an expert in caring for children, adolescents, and young adults with sarcomas.
Dana-Farber’s youngest patients are the inspiration behind the work of Dr. Janeway. Despite advances in understanding and treating cancer over the last several decades, pediatric cancer is still the leading cause of disease-related death in children in the United State, according to the National Cancer Institute (NCI). With her research, Dr. Janeway is hopes to deliver the benefits of precision medicine to more patients with childhood cancer and, ultimately, save more lives.
Dr. Janeway’s research is focused in three areas:
- Genomics – the observation of an entire genome (genes that make up an organism) of an organism; for example, the human body
- Precision oncology – the process of studying a patient’s disease on a genetic level to find targeted treatments for the individual’s specific cancer
- Bone sarcomas – cancer that forms in the bones; two classifications of bone sarcomas include osteosarcoma and Ewing sarcoma
Dr. Janeway leads clinical trials in osteosarcoma and Ewing sarcoma both as an independent investigator and as the Chair of the Children’s Oncology Group (COG) Bone Tumor Committee. Her work has uncovered the genetic errors or mutations that cause and promote difficult to treat childhood solid malignancies. She has leveraged this understanding to expand treatment opportunities and improve clinical trials for children with advanced childhood solid tumors.
Highlights of Dr. Janeway’s work includes:
- The National Cancer Institute-COG Pediatric MATCH trial is the first and largest national precision oncology clinical trial in the United States. As part of the leadership team for the MATCH trial, Dr. Janeway helped to demonstrate how sophisticated tumor profiling tests for pediatric patients can improve treatment and clinical trial opportunities.
- The main project in Dr. Janeway’s lab is the iCat2/GAIN consortium study. The study is focused on sequencing the difficult to treat solid cancers of over 500 pediatric patients to characterize the clinical impact of genomic sequencing. This research will eventually contribute to industry efforts to share and aggregate sequencing and clinical data to better understand childhood cancers.
- Additionally, Dr. Janeway’s team is working on data generation and sharing projects that will identify the genetic events that lead to osteosarcoma and Ewing sarcoma. This research will help uncover clinical and genomic factors that explain why patients develop these sarcomas and how to improve treatment options for the disease.
To contribute by check, please write "Dr. Janeway’s Giving Page" in the memo line, and send to:
Giving Pages
Dana-Farber Cancer Institute
Division of Development & The Jimmy Fund
10 Brookline Place West, 6th Fl
Brookline, MA 02445
617-632-6247
THANK YOU TO OUR TEAM MEMBERS
= Team CaptainTHANK YOU TO OUR TEAM DONORS
